Notícias e Destaques Estudos Clinicos - Medicamentos Fase III

PharmaMar, SA  Randomized, multi-center, open-label study in combination with dexamethasone vs. dexamethasone alone in patients with rel/ref MM. 
Bristol-Myers Squibb  Rev/dex with or without elotuzumab in the treatment of newly diagnosed MM (ELOQUENT 1); Rev/dex with or without elotuzumab in the treatment of relapsed/refractory MM (ELOQUENT 2) is active but no longer recruiting. 
MedImmune, Inc.  Cytoprotective agent to allow higher-dose therapy with auto-transplant. 
InSightec Inc.  Study comparing the safety and effectiveness of magnetic resonance guided focused ultrasound (MRgFUS) and external beam radiation (EBRT) for treatment of metastatic bone tumors and multiple myeloma. 
Millennium  1) Oral MLN9708 plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with newly diagnosed multiple myeloma; 2) oral MLN9708 plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in patients with relapsed/refractory myeloma. 
Onyx Therapeutics, Inc.  Various phase III trials, including one comparing carfilzomib/dex to bortezomib/dex. 
AB Science  Study to evaluate efficacy and safety of masitinib in patients with relapsed or refractory MM. Patients are randomized to receive bortezomib/dex with placebo or bortezomib/dex with masitinib. 
Novartis  Multicenter, randomized, double-blind, placebo-controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed MM. 
Celgene Corporation  Randomized study of pom/Vel/dex vs. Vel/dex in rel/ref mm. 
Celgene Corporation  Various trials are actively accruing patients, evaluating data, or soon to be opened. Check clinicaltrials.gov for complete listing of phase III lenalidomide trials. 
Millennium  Various trials in the US, Spain, and the UK for use with transplant, consolidation, induction, and maintenance therapy. 
Amgen  Randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (Zometa®) in the treatment of bone disease in subjects with newly diagnosed MM. 
Merck  Use of thalidomide, lenalidomide, bortezomib and vorinostat in the initial treatment of newly diagnosed MM (Myeloma XI). 

14/02/2014